Showing 4081-4090 of 9346 results for "".
- Rademikibart Shows High Long-Term Efficacy in Atopic Dermatitishttps://practicaldermatology.com/news/rademikibart-shows-high-long-term-efficacy-in-atopic-dermatitis/2486495/Rademikibart, a next-generation anti–IL-4 receptor alpha monoclonal antibody, demonstrated robust and sustained efficacy in moderate-to-severe atopic dermatitis (AD) through 52 weeks, according to Phase 3 RADIANT-AD data presented by Cheng Zhou, MD, at the American Academy of Dermatology (AAD) 20
- Tapinarof Shows Rapid Itch and Skin Improvement in Atopic Dermatitishttps://practicaldermatology.com/news/tapinarof-shows-rapid-itch-and-skin-improvement-in-atopic-dermatitis/2486493/New pooled Phase 3 data presented at the American Academy of Dermatology (AAD) 2026 Annual Meeting highlight the rapid onset and consistent efficacy of tapinarof cream 1% (VTAMA; Organon) in patients with moderate-to-severe atopic dermatitis (AD), including children as young as 2 years. Th
- Lebrikizumab Shows Durable Efficacy Through 4 Years in Atopic Dermatitishttps://practicaldermatology.com/news/lebrikizumab-shows-durable-efficacy-through-4-years-in-atopic-dermatitis/2486468/Long-term data from the Phase 3b ADlong study show that lebrikizumab provides sustained skin clearance and itch relief for up to four years in patients with moderate-to-severe atopic dermatitis (AD), according to findings presented at the American Academy of Dermatology (AAD) 2026 Annual Meeting.
- Nemolizumab Shows Efficacy in Pediatric Atopic Dermatitishttps://practicaldermatology.com/news/nemolizumab-shows-efficacy-in-pediatric-atopic-dermatitis/2486457/Nemolizumab, an IL-31 receptor alpha (IL-31Rα) antagonist, demonstrated favorable pharmacokinetics, sustained efficacy, and a consistent safety profile in children aged 2 to 11 years with moderate-to-severe atopic dermatitis (AD), according to Phase 2 data presented by Linda Stein Gold, MD, at th
- Upadacitinib Shows Strong Hair Regrowth in Alopecia Areatahttps://practicaldermatology.com/news/upadacitinib-shows-strong-hair-regrowth-in-alopecia-areata/2486456/Upadacitinib demonstrated robust efficacy in both adolescents and adults with severe alopecia areata (AA), with particularly strong responses observed in younger patients, according to a subgroup analysis of two Phase 3 trials presented by Melinda Gooderham, MD, MSc, at the American Academy of De
- Combination Therapy Improves Outcomes in Psoriatic Arthritis With Obesityhttps://practicaldermatology.com/news/combination-therapy-improves-outcomes-in-psoriatic-arthritis-with-obesity/2486455/Combination therapy with ixekizumab and tirzepatide demonstrated superior disease control compared with ixekizumab alone in adults with psoriatic arthritis (PsA) and overweight or obesity, according to Phase 3b TOGETHER-PsA results presented by Joseph F. Merola, MD, MMSc, at the American Academy
- Molecular Profiling Reveals Personalized Pathways in Skin Aginghttps://practicaldermatology.com/news/molecular-profiling-reveals-personalized-pathways-in-skin-aging/2486451/A translational biomarker study presented at the American Academy of Dermatology (AAD) 2026 Annual Meeting highlighted distinct molecular signatu
- Real-World Data Confirm Upadacitinib Effectiveness Across Body Regionshttps://practicaldermatology.com/news/real-world-data-confirm-upadacitinib-effectiveness-across-body-regions/2486450/Real-world evidence from the AD-VISE study demonstrates consistent and robust effectiveness of upadacitinib across body regions in patients with atopic dermatitis (AD), reinforcing outcomes observed in controlled clinical trials, according to data discussed by Melinda Gooderham, MD, MSc, at the A
- Transcriptomic Study Identifies IL-1β Axis in Hidradenitis Suppurativahttps://practicaldermatology.com/news/transcriptomic-study-identifies-il-1b-axis-in-hidradenitis-suppurativa/2486448/Comprehensive transcriptomic profiling of hidradenitis suppurativa (HS) highlights a dominant macrophage-derived IL-1β/NLRP3 inflammasome axis, p
- Envudeucitinib Outperforms Placebo and Apremilast in Phase 3 Psoriasis Trialshttps://practicaldermatology.com/news/envudeucitinib-outperforms-placebo-and-apremilast-in-phase-3-psoriasis-trials/2486447/Envudeucitinib, a next-generation oral tyrosine kinase 2 (TYK2) inhibitor, demonstrated significant efficacy and a favorable safety profile in patients with moderate-to-severe plaque psoriasis, according to Phase 3 data from the ONWARD 1 and ONWARD 2 trials presented by Andrew Blauvelt, MD, MBA,